SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing high volatility driven by a short-seller report that has triggered intense community debate regarding the company's tax status and growth narrative. Investors are actively discussing the firm's response to these claims, alongside optimistic sentiment surrounding its recent technological partnerships and upcoming strategic shifts.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors react to a significant expansion of its partnership with NVIDIA to power safety-critical edge AI systems for robotics and industrial applications. The community is actively discussing the stock's potential for a broader valuation reset, with many highlighting the companys transition from a legacy name to a vital infrastructure play in the physical AI sector.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing a surge in trading volume and bullish sentiment driven by clinical trial progress, including favorable updates on their prostate cancer treatment that have stoked speculation about potential partnership or buyout interest. The community is actively discussing the stock's undervaluation compared to its large market potential, with many investors pointing to recent institutional accumulation and the expectation of upcoming regulatory milestones as catalysts for a potential short squeeze.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc is seeing a surge in investor interest and strong upward momentum, driven by growing optimism around the company's expansion into the peptide market and strategic moves to integrate compounded treatments. The community is actively discussing the stock's short squeeze potential, fueled by high short interest and anticipation that upcoming regulatory developments will serve as further catalysts for growth.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant volatility following a failed orbital deployment of a satellite by Blue Origin, leading to intense community debate over execution risks versus the company's long-term growth thesis. While some investors are viewing the price drop as a strategic buying opportunity supported by insurance coverage and a robust production pipeline, others remain critical of the company's reliance on external launch providers and the resulting timeline delays.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is experiencing heightened investor interest and increased volume following a definitive agreement to acquire Serra Verde Group for approximately $2.8 billion, a move described by the community as a major strategic pivot to secure non-Asian supply chain dominance. While some market participants are debating the short-term impacts of the associated share dilution, sentiment remains largely focused on the potential for long-term supply chain leverage and the stock's role in the broader shift toward domestic critical mineral independence.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing massive retail and institutional attention following a new executive order that fast-tracks regulatory pathways and funding for psychedelic drug research, specifically highlighting ibogaine. The community is actively debating the stock's potential for a short squeeze driven by its extremely low tradable float, while some investors urge caution regarding potential dilution and the long-term reality of clinical timelines.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion Inc. (INFQ) is seeing a surge in investor interest driven by its strategic partnership with NVIDIA, which specifically selected the company to deploy its new quantum-focused AI toolset. The community is actively discussing the stock's potential as a mispriced leader in the quantum sector, with many participants focusing on high-volume trading activity and the company's expanding role in quantum sensing and space infrastructure.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to significant community speculation regarding the potential appointment of a former executive as the next director of the FDA's CBER, which investors believe would expedite the approval of Deramiocel. The community remains hyper-focused on this regulatory transition, viewing the potential shift in leadership as a major de-risking event that could catalyze a substantial move in the share price.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI Life Sciences N.V.

ATAI is trending as investors react to a potential $2 billion buyout process for its lead BPL-003 asset and excitement surrounding the company's Q2 Phase 3 trial initiation. The community is actively discussing the stock's long-term potential as a psychedelic platform, with many highlighting its institutional backing and the significant regulatory tailwinds shifting the sector's outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
